Protalix Biotherapeutics, Inc.

291 articles about Protalix Biotherapeutics, Inc.

• Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock

  2/11/2021

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it intends to make a public offer of 6,500,000 shares

• Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock

  2/11/2021

  Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the "Company"), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system,

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLD Symposium™ 2021

  2/10/2021

  Protalix BioTherapeutics today announced that final results from the Phase III BRIDGE clinical trial (NCT03018730) of pegunigalsidase alfa (PRX–102)

• Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

  2/1/2021

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will deliver an oral presentation and a poster presentation at the 17th Annual WORLDSymposium

• Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January

  1/4/2021

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company's management will participate in virtual 1x1 investor meetings

• Protalix BioTherapeutics Issues 2020 Letter to Shareholders

  12/30/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced the following letter from its Presiden

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

  12/30/2020

  A decline trend in patients' renal function on agalsidase alfa was attenuated and improved to be similar to normal renal function decline when switched to PRX-102

• 

  Protalix's Fabry Disease Treatment Hits the Mark in Phase III Switch-Over Study

  12/30/2020

  Fabry disease is a rare, X-linked inherited disease that results from abnormal deposits of a fatty substance in blood vessels.

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

  11/27/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chie

• Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

  10/29/2020

  Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, reported financial results for the third quarter ended September 30, 2020, and provided a business update on recent corporate and clinical developments.

• Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

  10/29/2020

   Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today announced that it has rescheduled today's conferenc

• Protalix BioTherapeutics to Participate in Virtual Investor KOL Roundtable

  10/26/2020

  Protalix BioTherapeutics, Inc. announced that on Wednesday, October 28, 2020, at 10:00 a.m. EDT, it will participate in the Virtual KOL Roundtable, covering both the Company and pegunigalsidase alfa, or PRX–102, the Company's lead drug candidate for the treatment of Fabry Disease.

• Protalix BioTherapeutics to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on October 29, 2020

  10/22/2020

  Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced that it will release its financial results for the third quarter 2020 and business update on Thursday, October 29, 2020.

• Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

  10/2/2020

  - Program grants access to investigational treatment for Fabry disease patients that cannot be adequately treated with any FDA-approved drugs and provides guidance to treating physicians   [02-October-2020]   BOSTON and CARMIEL, Israel , Oct. 2, 2020 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-foc

• Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing Standards

  9/8/2020

  Protalix BioTherapeutics, Inc. announced that it received, on September 3, 2020, notification from the NYSE American LLC that the Company has regained compliance with all of the continued listing standards set forth in Part 10 of the NYSE American Company Guide.

• Protalix BioTherapeutics to Present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

  9/8/2020

  Protalix BioTherapeutics, Inc. announced that Dror Bashan, the Company's President and Chief Executive Officer will present in the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Tuesday, September 15, 2020 at 12:00 PM, Eastern Time.

• Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease

  8/24/2020

  Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced completion of the treatment period of its Phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX–102, for the proposed treatment of Fabry disease.

• Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. FDA Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review

  8/11/2020

  Protalix BioTherapeutics, Inc. together with its development and commercialization partner Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration has accepted the Biologics License Application and granted Priority Review designation for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease.

• Protalix BioTherapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/10/2020

  Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2020,

• Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020

  8/6/2020

   Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system